Neurogene Inc. Files 2024 10-K
Ticker: NGNE · Form: 10-K · Filed: Mar 24, 2025 · CIK: 1404644
Sentiment: neutral
Topics: 10-K, pharmaceuticals, annual-report
TL;DR
Neurogene Inc. 2024 10-K filed. Financials and biz ops detailed.
AI Summary
Neurogene Inc. filed its 2024 10-K on March 24, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Neoleukin Therapeutics, Inc., is involved in the pharmaceutical preparations industry. The filing details its financial performance and business operations for the year.
Why It Matters
This filing provides investors and the public with a comprehensive overview of Neurogene Inc.'s financial health and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Neurogene Inc. faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Neurogene Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-24 (date) — Filing date
- Neoleukin Therapeutics, Inc. (company) — Former company name
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What was Neurogene Inc.'s former company name?
Neurogene Inc.'s former company name was Neoleukin Therapeutics, Inc., with a date of name change on 20190812.
What is Neurogene Inc.'s Standard Industrial Classification code?
Neurogene Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
When did Neurogene Inc. file its 10-K report?
Neurogene Inc. filed its 10-K report on 20250324.
What fiscal year does this 10-K report cover?
This 10-K report covers the fiscal year ending on 20241231.
What is Neurogene Inc.'s business address?
Neurogene Inc.'s business address is 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY 10011.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 24, 2025 regarding Neurogene Inc. (NGNE).